These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 8559613)

  • 1. Intravenous cysteamine therapy for nephropathic cystinosis.
    Gahl WA; Ingelfinger J; Mohan P; Bernardini I; Hyman PE; Tangerman A
    Pediatr Res; 1995 Oct; 38(4):579-84. PubMed ID: 8559613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of the effectiveness of cysteamine and phosphocysteamine in elevating plasma cysteamine concentration and decreasing leukocyte free cystine in nephropathic cystinosis.
    Smolin LA; Clark KF; Thoene JG; Gahl WA; Schneider JA
    Pediatr Res; 1988 Jun; 23(6):616-20. PubMed ID: 3393396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Intra-leukocyte cystine in cystinosis treated with cysteamine].
    Ged C; Jean G; Tete MJ; Broyer M; Kamoun P
    Ann Biol Clin (Paris); 1991; 49(9):482-6. PubMed ID: 1789502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term treatment of cystinosis in children with twice-daily cysteamine.
    Dohil R; Gangoiti JA; Cabrera BL; Fidler M; Schneider JA; Barshop BA
    J Pediatr; 2010 May; 156(5):823-7. PubMed ID: 20138296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of cysteamine therapy in nephropathic cystinosis.
    Yudkoff M; Foreman JW; Segal S
    N Engl J Med; 1981 Jan; 304(3):141-5. PubMed ID: 7442733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cysteamine therapy for children with nephropathic cystinosis.
    Gahl WA; Reed GF; Thoene JG; Schulman JD; Rizzo WB; Jonas AJ; Denman DW; Schlesselman JJ; Corden BJ; Schneider JA
    N Engl J Med; 1987 Apr; 316(16):971-7. PubMed ID: 3550461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cysteamine in the treatment of cystinosis in children. In vitro and in vivo studies].
    Louis JJ; Guibaud P; Dumoulin R; Parchoux B; Zabot MT; Bureau J; Baltassat P; Frederich A; Larbre F
    Pediatrie; 1984 Dec; 39(8):619-33. PubMed ID: 6535971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching from immediate- to extended-release cysteamine in nephropathic cystinosis patients: a retrospective real-life single-center study.
    Ahlenstiel-Grunow T; Kanzelmeyer NK; Froede K; Kreuzer M; Drube J; Lerch C; Pape L
    Pediatr Nephrol; 2017 Jan; 32(1):91-97. PubMed ID: 27350621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cystinosis: renal glomerular and renal tubular function in relation to compliance with cystine-depleting therapy.
    Nesterova G; Williams C; Bernardini I; Gahl WA
    Pediatr Nephrol; 2015 Jun; 30(6):945-51. PubMed ID: 25526929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous delivery of cysteamine for the treatment of cystinosis: association with hepatotoxicity.
    Bendel-Stenzel MR; Steinke J; Dohil R; Kim Y
    Pediatr Nephrol; 2008 Feb; 23(2):311-5. PubMed ID: 17668247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cystinosis. Intracellular cystine depletion by aminothiols in vitro and in vivo.
    Thoene JG; Oshima RG; Crawhall JC; Olson DL; Schneider JA
    J Clin Invest; 1976 Jul; 58(1):180-9. PubMed ID: 932205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cysteamine eyedrops for treatment of corneal cysteine deposits in infantile cystinosis].
    Gräf M; Grote A; Wagner F
    Klin Monbl Augenheilkd; 1992 Jul; 201(1):48-50. PubMed ID: 1513127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics and pharmacodynamics of cysteamine in nephropathic cystinosis patients.
    Bouazza N; Tréluyer JM; Ottolenghi C; Urien S; Deschenes G; Ricquier D; Niaudet P; Chadefaux-Vekemans B
    Orphanet J Rare Dis; 2011 Dec; 6():86. PubMed ID: 22195601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse reactions to oral cysteamine use in nephropathic cystinosis.
    Corden BJ; Schulman JD; Schneider JA; Thoene JG
    Dev Pharmacol Ther; 1981; 3(1):25-30. PubMed ID: 7307866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The origin of halitosis in cystinotic patients due to cysteamine treatment.
    Besouw M; Blom H; Tangerman A; de Graaf-Hess A; Levtchenko E
    Mol Genet Metab; 2007 Jul; 91(3):228-33. PubMed ID: 17513151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Corneal crystals in nephropathic cystinosis: natural history and treatment with cysteamine eyedrops.
    Gahl WA; Kuehl EM; Iwata F; Lindblad A; Kaiser-Kupfer MI
    Mol Genet Metab; 2000; 71(1-2):100-20. PubMed ID: 11001803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of oral phosphocysteamine and rectal cysteamine in cystinosis.
    van't Hoff WG; Baker T; Dalton RN; Duke LC; Smith SP; Chantler C; Haycock GB
    Arch Dis Child; 1991 Dec; 66(12):1434-7. PubMed ID: 1776892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term treatment of infantile nephropathic cystinosis with cysteamine.
    da Silva VA; Zurbrügg RP; Lavanchy P; Blumberg A; Suter H; Wyss SR; Lüthy CM; Oetliker OH
    N Engl J Med; 1985 Dec; 313(23):1460-3. PubMed ID: 4058549
    [No Abstract]   [Full Text] [Related]  

  • 19. Halitosis in cystinosis patients after administration of immediate-release cysteamine bitartrate compared to delayed-release cysteamine bitartrate.
    Besouw M; Tangerman A; Cornelissen E; Rioux P; Levtchenko E
    Mol Genet Metab; 2012 Sep; 107(1-2):234-6. PubMed ID: 22832073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of cystinosis with cysteamine. A pilot study determining dose and form of application.
    Bergonzi E; Herren A; Lavanchy P; Bühlmann C; Wyss SR; Lüthy C; Oetliker O
    Helv Paediatr Acta; 1981 Nov; 36(5):437-43. PubMed ID: 7031022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.